<DOC>
	<DOCNO>NCT01913847</DOCNO>
	<brief_summary>The purpose study investigate safety clinical efficacy HGP1207 ( Sildenafil ) subject pulmonary hypertension associate systolic heart failure .</brief_summary>
	<brief_title>Safety Efficacy Study HGP1207 Patients With Pulmonary Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Patients diagnosis chronic heart failure ( NYHA Class II III ) LVEF ≤ 40 % Elevated systolic PAP : ≥ 40 mmHg Patients must treat ACE inhibitor , ARB , betablocker , aldosterone antagonist stable dose least 4 week prior visit 1 Patients pulmonary hypertension associate chronic obstructive pulmonary disease , interstitial lung disease , chronic thromboembolism unclear/multifactorial mechanism Patients receive Nitrates/NO donor Cytochrome P450 3A4 inhibitor within 30 day prior visit 1 Patients receive calcium channel blocker , endothelin receptor antagonist , prostacyclin analogue , phosphodiesterase 5 inhibitor within 90 day prior visit 1 History hypersensitivity allergy sildenafil excipients formulation Patients hypertension ( sitSBP &gt; 170 mmHg sitDBP &gt; 100 mmHg ) hypotension ( sitSBP &lt; 90 mmHg sitDBP &lt; 50 mmHg ) Patients medical condition ( i.e. , alcoholism , drug abuse ) may cause patient noncompliant protocol , confound data interpretation Pregnant females child bear potential negative pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>